

August 31, 2020

To Whom It May Concern,

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara, Chief Executive Officer
(First Section of TSE: Code 4581)
Contact: Shinichi Tanaka, General Manager
Corporate Communications
(Tel: +81-3-3985-2020)

**Notice Concerning the Termination of the Agreement Between Taisho Pharmaceutical Co., Ltd.
and Takeda Pharmaceutical Co., Ltd. on the Distribution of Prescription Drugs of Biofermin
Pharmaceutical Co., Ltd.**


Taisho Pharmaceutical Holdings Co., Ltd. (“the Company”) announced that Taisho Pharmaceutical Co., Ltd. (Head office: Toshima-ku, Tokyo, Japan; Chief Executive Officer: Shigeru Uehara, “Taisho”), a wholly owned subsidiary of the Company, and Takeda Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; Representative Director, President & CEO: Christophe Weber, “Takeda”) agreed to terminate the distribution of prescription drugs manufactured and distributed by Biofermin Pharmaceutical Co., Ltd. (Head office: Kobe, Japan; President, Representative Director: Osamu Kitatani, “Biofermin Pharmaceutical”), the Company’s consolidated subsidiary, through Takeda by the end of December 2020 (the “Termination Agreement”).

Regarding Biofermin Pharmaceutical’s products, Taisho and Biofermin Pharmaceutical signed an exclusive sales contract in July 2013. In addition, Taisho agreed to grant Takeda a domestic distributorship of Biofermin Pharmaceutical’s products for a certain period of time and has distributed Biofermin Pharmaceutical’s products through Takeda since January 2014. The OTC drug and quasi-drug transactions through Takeda terminated at the end of September 2017, and Taisho has conducted sales since October 2017. As a result of the Termination Agreement, all domestic sales of Biofermin Pharmaceutical’s products including prescription drugs will be conducted by Taisho from January 2021 onwards.

The impact of the Termination Agreement on the Company’s consolidated business results is minor.

(Reference) Flow of prescription drug transactions

- Before change (currently):



- After change (from January 2021 onward):

